BCL11A Is a Triple-Negative Breast Cancer Gene with Critical Functions in Stem and Progenitor Cells
Researchers report that the transcription factor BCL11A is overexpressed in triple-negative breast cancer (TNBC) including basal-like breast cancer (BLBC) and that its genomic locus is amplified in up to 38% of BLBC tumors. Exogenous BCL11A overexpression promotes tumor formation, whereas its knockdown in TNBC cell lines suppresses their tumorigenic potential in xenograft models. [Nat Commun] Full Article|Press Release
BRCA1-IRIS Inactivation Overcomes Paclitaxel Resistance in Triple Negative Breast Cancers
Researchers investigated the role of BRCA1-IRIS as a novel treatment target for triple negative breast cancers (TNBC) and their paclitaxel-resistant recurrences. They analyzed the response of BRCA1-IRIS overexpressing normal mammary cells or established TNBC cells silenced from BRCA1-IRIS to paclitaxel in vitro and in vivo. [Breast Cancer Res] Abstract|Full Article
Targeting HER2 for the Treatment of Breast Cancer
Treatment with the anti-HER2 monoclonal antibody trastuzumab has revolutionized the outcome of patients with this aggressive breast cancer subtype, but intrinsic and acquired resistance is common. Growing understanding of the biology and complexity of the HER2 signaling network and of potential resistance mechanisms has guided the development of new HER2-targeted agents. [Annu Rev Med] Abstract
Visit our reviews page to see a complete list of reviews in the mammary cell research field.
INDUSTRY NEWS
OncoSec Medical Plans to Initiate Pilot Study in Triple Negative Breast Cancer
OncoSec Medical Inc. plans to initiate a pilot study to assess IL-12 ImmunoPulse in patients with triple negative breast cancer (TNBC). This pilot study is designed to assess whether IL-12 ImmunoPulse increases TNBC tumor immunogenicity by driving a pro-inflammatory cascade of events that leads to increases in cytotoxic tumor-infiltrating lymphocytes. [OncoSec Medical Inc.] Press Release
Nature Owner Merges with Publishing Giant
Consolidation is afoot in scientific publishing. Macmillan Science and Education, the London-based publisher of Nature and Scientific American, will merge with Berlin-based Springer Science+Business Media, one of the world’s largest science publishers. [Nature News] Editorial
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Mammary Cell News? Click here to submit!